Schizophrenia

Neurology·MeSH: Schizophrenia

Prevalence

300.0 / 100K

Incidence

15.0 / 100K/yr

89 drugs in development·49 companies·72 clinical trials

Drug Pipeline by Phase

Approved(30)
DrugCompany
aripiprazoleMylan II B.V. (MYL)
ARISTADAAlkermes plc. (ALKS)
ARISTADA INITIOAlkermes plc. (ALKS)
CaplytaIntra-Cellular Therapies, Inc. (ITCI)
cobenfyBRISTOL MYERS SQUIBB CO (BMY)
fanaptVanda Pharmaceuticals Inc. (VNDA)
INVEGA HAFYERA / BYANNLIAlkermes plc. (ALKS)
INVEGA SUSTENNA / XEPLIONAlkermes plc. (ALKS)
INVEGA TRINZA / TREVICTAAlkermes plc. (ALKS)
LYBALVIAlkermes plc. (ALKS)
NUPLAZIDACADIA PHARMACEUTICALS INC (ACAD)
paliperidoneInventiva S.A. (IVA)
perphenazineMylan II B.V. (MYL)
perseris kitIndivior Pharmaceuticals, Inc. (INDV)
prochlorperazine edisylateNEXUS BIOPHARMA INC (NEXS)
RISPERDAL CONSTAAlkermes plc. (ALKS)
risperidoneSynthorx, Inc. (THOR)
risperidoneDR REDDYS LABORATORIES LTD (RDY)
risperidoneAlphaTON Capital Corp (ATON)
risperidoneANI PHARMACEUTICALS INC (ANIP)
risperidoneAptinyx Inc. (APTX)
risperidoneSUNSET ISLAND GROUP (SUN)
risperidoneREATA PHARMACEUTICALS INC (RETA)
risperidonePrestige Consumer Healthcare Inc. (PBH)
risperidoneNANOMIX CORP (BTHI)
risperidoneAmneal Pharmaceuticals, Inc. (AMRX)
risperidonePRECISION BIOSCIENCES INC (DTIL)
risperidoneLANNETT CO INC (LCI)
thiothixeneAmneal Pharmaceuticals, Inc. (AMRX)
uzedyTeva Pharmaceutical Industries Limited (TEVA)
Phase 3(22)
DrugCompany
aticaprantGH Research PLC (GHRS)
BXCL501 (IGALMI® for approved indications)BioXcel Therapeutics, Inc. (BTAI)
bysantiVanda Pharmaceuticals Inc. (VNDA)
lb-102LB PHARMACEUTICALS INC (LBRX)
lumateperoneIntra-Cellular Therapies, Inc. (ITCI)
lumateperone LAIIntra-Cellular Therapies, Inc. (ITCI)
nbi-1117568NEUROCRINE BIOSCIENCES INC (NBIX)
nbi-1117570NEUROCRINE BIOSCIENCES INC (NBIX)
OlanzapineAlkermes plc. (ALKS)
OLZ/SAMAlkermes plc. (ALKS)
oral olanzapineTeva Pharmaceutical Industries Limited (TEVA)
oral paliperidone erBRAIN SCIENTIFIC INC. (BRSF)
oral risperidoneBRAIN SCIENTIFIC INC. (BRSF)
quetiapineBRAIN SCIENTIFIC INC. (BRSF)
roluperidoneMinerva Neurosciences, Inc. (NERV)
sep-363856NYMOX PHARMACEUTICAL CORP (NYMXF)
tak-063Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-063TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-063Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tv-44749Teva Pharmaceutical Industries Limited (TEVA)
xanomelineKaruna Therapeutics, Inc. (KRTX)
xanomeline/trospiumGH Research PLC (GHRS)

Compare drugs

aripiprazole vs ARISTADAaripiprazole vs ARISTADA INITIOaripiprazole vs Caplyta

Frequently asked questions

How many drugs are in development for Schizophrenia?

BioSniper tracks 89 drugs in development for Schizophrenia across 49 companies.

How many clinical trials target Schizophrenia?

There are 72 clinical trials targeting Schizophrenia tracked by BioSniper.

What is the prevalence of Schizophrenia?

The estimated prevalence of Schizophrenia is approximately 300.0 per 100,000 population.

Deep-dive into Schizophrenia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis